康方生物每一次试验数据披露,都背负着投资者对“惊艳结果”的期待,都可能带来股价的大起大落文 |凌馨编 |王小图/视觉中国被认为是中国创新药的“DeepSeek”的康方生物,2025年4月28日收盘跌11.02%,盘中一度跌去16.53%。大跌发生在康方生物宣布两项重大利好之后。4月25日,该公司先后宣布两项重要的新药获批信息:一款药首次在美国获批上市,另一款是用于一线治疗非小细胞肺癌的依沃西(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.